Related Experiment Video

Updated: May 29, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.6K

Noninsulin Diabetes Medications in Hospitalized Children and Adolescents

Mili Vakharia1

  • 1Division of Pediatric Diabetes and Endocrinology, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children's Hospital, 1020 MS: BCM320, 6621 Fannin Street, Houston, TX, USA.

Critical Care Nursing Clinics of North America
|January 31, 2025
PubMed

Insights

Pediatric diabetes is increasing globally. This review examines noninsulin medication use for children with hyperglycemia in acute care, addressing a gap in current literature for inpatient settings.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Pharmacology

Background:

  • Pediatric diabetes, including type 1, type 2, and maturity onset diabetes of youth, is increasingly prevalent worldwide.
  • Treatment strategies for pediatric diabetes are diverse and depend on the specific type and clinical context.
  • Limited evidence exists for noninsulin medication use in managing pediatric diabetes within inpatient settings.

Purpose of the Study:

  • To review the use of noninsulin medications for managing hyperglycemia in pediatric patients in acute care settings.
  • To address the gap in literature regarding noninsulin pharmacotherapy for hospitalized children and adolescents with diabetes.

Main Methods:

  • Literature review focusing on noninsulin medication management in pediatric acute care.
  • Analysis of clinical presentations and settings for critically and noncritically ill children with hyperglycemia.

Main Results:

  • Noninsulin medications may offer viable options for specific pediatric diabetes cases in acute care.
  • Further research is needed to establish clear guidelines for noninsulin use in inpatient pediatric diabetes management.

Conclusions:

  • Noninsulin pharmacotherapy represents an area for further investigation in pediatric inpatient diabetes care.
  • Evidence-based guidelines are needed to support the safe and effective use of noninsulin agents for hospitalized children with hyperglycemia.

Keywords:
GLP-1 agonistsHyperglycemiaInpatientMetforminPediatric diabetesSGLT-2 inhibitors

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.3K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
162
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
133
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149